Rigel Pharmaceuticals, Inc. provides preliminary unaudited revenue guidance for the fourth quarter of 2021. For the year, the company expects total revenue of approximately $20.4 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9825 USD | +1.35% | -3.68% | -32.24% |
May. 07 | Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.24% | 172M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.73% | 22.28B | |
-11.90% | 22.41B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter of 2021